1 / 18

A prospective randomized trial N. Mottet, M Peneau, JJ Mazeron, V Molinié and P Richaud

RADIOTHERAPY COMBINED WITH ANDROGEN DEPRIVATION (ADT) vs ADT IN CLINICALLY LOCALLY ADVANCED PROSTATE CANCER. A prospective randomized trial N. Mottet, M Peneau, JJ Mazeron, V Molinié and P Richaud. Disclosures. N. Mottet: Advisor and paid consultant for Takeda

heinz
Download Presentation

A prospective randomized trial N. Mottet, M Peneau, JJ Mazeron, V Molinié and P Richaud

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RADIOTHERAPY COMBINED WITH ANDROGEN DEPRIVATION (ADT) vs ADT IN CLINICALLY LOCALLY ADVANCED PROSTATE CANCER A prospective randomized trial N. Mottet, M Peneau,JJ Mazeron, V Molinié and P Richaud

  2. Disclosures N. Mottet: Advisor and paid consultant for Takeda Received compensations for lectures and clinical trials Protocol fully funded by Takeda France Protocol independently written from the company Data monitoring and statistical analysis performed by Mapi An IDMC committee had full access to all data

  3. Radiotherapy with prolonged ADT: superior to radiotherapy alone [EORTC 22863, 22961, RTOG 8531, 9202] ADT: sometimes used alone in locally advanced PCa. However - Combined modality superior to ADT (NSAA) [Widmark Lancet 2009] - No data available with an LHRH agonist Rational for a randomized trial: 3 years ADT ± Radiotherapy. BACKGROUND

  4. STUDY POPULATION Age < 80, Karnofsky over 70 Prostate Cancer histologically confirmed T3/T4 or pT3 ( biopsy) N0/M0 Never treated except TURP for obstructive syndrome PRIMARY ENDPOINT 5 years overall Progression free survival: biological and clinical Expected benefit: 15% at 5 years SECONDARY CRITERIA Survival (Overall and specific) Quality of life (QLQ-c30 and QLQ-PR25) Tolerance to treatment (SOMALENT) STUDY PROTOCOL

  5. STUDY DESIGN R1 – M0b < 90 days Treatment period : 3 years (ADT) (1 visit / 6 months) Without treatment period : 2 years (1 visit / 6 months) Post protocol follow-up R1 R2 2 months M6 M12 M18 M24 M30 V V V V M36 3,5 5 4,5 4 M0b randomization M0a Selection M36 V V M6 M12 M18 M24 M30 V V 3,5 5 4,5 4 Centralized PSA (Hybritech) / 6 months Acute toxicity RTOG: M6

  6. ADT: Leuprorelin SR 11.25 mg SC / 3 months + Flutamide 750 mg / day, Month 1 Radiotherapy : Total dose 70 ± 4 Gy. 35 fractions (±2) Pelvis (4 fields technique) 48 ± 2 Gy Prostate boost: 3D conformal Standardized planning OF NOTE • Radiotherapy quality control: independent committee validated each treatment • Independent Data monitoring committee TREATMENT

  7. Randomised patients N=264 ADT group N=131 Combined group N=133 ITT Population N=263 ADT group N=130 Combined group N=133 PP Population N=237 ADT group N=128 Combined group N=109 POPULATION Planed number of patients = 256 Included patients N=273 40 French sites From March 2000 to December 2008 LVLP Inclusion: 2000 – 2003 Data base locked: 07/2009 Median follow up: 67 months

  8. PATIENTS

  9. % patients Years ADT group Combined group RESULTS 1 5 years overall PFS (ASTRO definition) ADT group Combined group ADT group Combined group Median PFS:7.7 vs 1.7 years p < 0.0001

  10. RESULTS 2 5 years overall PFS (Phoenix definition) ADT group Combined group % patients Years ADT group Combined group Median PFS: 6.96 vs 3.46 years p = 0.0005

  11. PFS AND BASELINE PSA (Phoenix definition ) 100% 90% 80% 70% 60% 50% % patients 40% 30% p=0.001 20% RR : 5.22 [3.05; 8.95]; p=0.0011 p = 0.0053 10% 0% 1 2 3 4 5 Baseline PSA<20 ng/ml: ADT group combined group Baseline 20<PSA<50 ng/ml: ADT group combined group Baseline PSA>=50 ng/ml: ADT group combined group

  12. CLINICAL PFS ITT population ADT group Combined group % patients Years ADT group Combined group 88.7% vs 62.3% p < 0.001

  13. LOCO-REGIONAL PFS ITT population ADT group Combined group % patients RR : 3.7 [1.9; 7.4] p<0.0002 Years ADT group Combined group 90.3% vs 70.77% p < 0.0002

  14. METASTATIC PFS ITT population ADT group Combined group % patients Years ADT group Combined group 97% vs 89.23%p = 0.0183

  15. OVERALL SURVIVAL ITT population ADT group Combined group % patients Years ADT group Combined group At 5 years: 71.5% vs 71.4% p = 0.7882

  16. SPECIFIC SURVIVAL ITT population ADT group Combined group % patients % patients Years Years ADT group Combined group At 5 years: 93.2% vs 86.1% p = 0.11

  17. SUMMARY In patients with locally advanced PCa, addition of local radiotherapy to 3 years of LHRH significantly reduces the progression risk (biological, clinical, metastatic). The benefit appears to be related mainly to improved loco-regional control. A prolonged follow up is needed to see a potential survival impact

  18. CONCLUSION This reduction of disease progression confirms that radiotherapy combined with ADT should be one standard for patients with a locally advanced disease and a significant life expectancy.

More Related